ClinicalTrials.gg
Active, not recruitingNCT06564142Updated May 15, 2026

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

A Phase 3 interventional study of Povetacicept and Placebo (matched to Povetacicept) in Immunoglobulin A Nephropathy, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex. Active, not recruiting at 318 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex (part of Vertex Pharmaceuticals Incorporated) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
605
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 74 studies in Glomerulonephritis, IGA with a site in United States — 26 open to participants now, 38 under way, 17 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
2nd of 68
605 · median 64
Started
2024
with 5 others
Phase 3
22 of 74
9 open now
Primary completion
2028-01
later than 16 of 37 live
Registered
49th of 74
by date

Among the 74 studies in Glomerulonephritis, IGA with a site in United States, this one is the 2nd largest by enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2024, is one of 22 in phase 3, reaches primary completion later than 16 of the 37 other live ones, and was the 49th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

26 of the 74 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.

03

Conditions studied

  • Immunoglobulin A Nephropathy

Keywords

  • IgAN
  • Berger's disease
  • glomerulonephritis
  • IgA nephropathy
  • ALPN-303
  • BAFF
  • BLyS
  • APRIL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosed IgAN, with confirmation
  • 24-hr proteinuria excretion ≥1.0 g/day or 24-hour uPCR ≥0.75 g/g
  • Estimated (eGFR) ≥ 30 mL/min/1.73m\^2
  • Stable angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARBs) as per protocol specification

Key Exclusion Criteria:

  • Have received any treatment or procedures (including , oral immunosuppressive agents, B cell or plasma cell targeted therapies, complement targeted therapies, herbal medicines per protocol, and tonsillectomy) within a per protocol
  • Rapidly progressive glomerulonephritis with eGFR reduction >50% within 12 weeks of the start of screening

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
605 participants (actual)

Study arms

  • Experimental
    Povetacicept

    Participants will be randomized to receive Povetacicept.

    Drug: Povetacicept

  • Placebo comparator
    Placebo

    Participants will be randomized to receive placebo matched to Povetacicept.

    Drug: Placebo (matched to Povetacicept)

Interventions

  • Subcutaneous injection administration.

    Also known as: ALPN-303

  • DrugPlacebo (matched to Povetacicept)

    Placebo matched to Povetacicept subcutaneous injection administration.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (uPCR) at Week 36

    Time frame: From Baseline at Week 36

  2. Total Estimated Glomerular Filtration Rate (eGFR) Slope Through Week 104

    Time frame: From Baseline Through Week 104

Secondary outcomes

  1. Change from Baseline in Serum Gd-IgA1 at Week 36

    Time frame: From Baseline at Week 36

  2. Proportion of Participants to Achieve Hematuria Resolution at Week 36 (Among Participants With Hematuria at Baseline)

    Time frame: From Baseline at Week 36

  3. Change From Baseline in eGFR at Week 104

    Time frame: From Baseline at Week 104

  4. Time to Kidney Disease Progression Through Week 104

    Kidney disease progression defined as greater than or equal to (≥) 30% decline in eGFR, end stage kidney disease, or non-accidental death

    Time frame: From Baseline Through Week 104

07

Study locations

318 sites

Showing the first 100 of 318 sites across 33 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jan 2028, 41 months after the start.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 21, 2024
StartActual
Aug 30, 2024
Primary completionEst.
Jan 30, 2028
CompletionEst.
Jan 30, 2028
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06564142
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Aug 30, 2024
Primary completion
Jan 30, 2028 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
May 15, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povetacicept

Start the discussion